You just read:

Cancer Prevention Pharmaceuticals Completes Target Enrollment in Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/sulindac in Patients with Familial Adenomatous Polyposis

News provided by

Cancer Prevention Pharmaceuticals, Inc.

Apr 04, 2016, 08:00 ET